biostudies-literatureUnknown16Siebert SJanssen Research &amp; Development, LLC<h4>Background</h4>Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit.<h4>Objectives</h4>Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses in patients with active psoriatic arthritis (PsA).<h4>Design</h4>DISCOVER-2 randomized 739 biologic-naïve patients with active PsA (swollen/tender joint counts each ⩾5, C-reactive protein (CRP) ⩾0.6 mg/dL) to guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W) or placebo. Guselkumab-randomized participants with available serum biomarker data (randomly selected to reflect demographic and disease characteristics of the DISCOVER-2 population) comprised inflammatory (<i>N</i> = 100) and collagen (<i>N</i> = 178) biomTherapeutic advances in musculoskeletal disease1759720X241283536https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528637biostudies-literatureCorrelation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.PMC11528637Rahman PGuma MSiebert SRaychaudhuri SPChen WChakravarty SDSchett GLavie FGao SfalseCorrelation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.<h4>Background</h4>Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit.<h4>Objectives</h4>Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses in patients with active psoriatic arthritis (PsA).<h4>Design</h4>DISCOVER-2 randomized 739 biologic-naïve patients with active PsA (swollen/tender joint counts each ⩾5, C-reactive protein (CRP) ⩾0.6 mg/dL) to guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W) or placebo. Guselkumab-randomized participants with available serum biomarker data (randomly selected to reflect demographic and disease characteristics of the DISCOVER-2 population) comprised inflammatory (<i>N</i> = 100) and collagen (<i>N</i> = 178) biom2024-01-01T00:00:00Z20242026-06-01T06:52:37.472Z2025-04-06T14:23:36.176ZS-EPMC115286373949388810.1177/1759720X241283536